Share this post on:

Name :
LRIG1 Polyclonal Antibody

Documents :
DataSheet Material Safety Data Sheets (MSDS)

Description :
Polyclonal antibody to LRIG1

Tested applications :
WB

Species reactivity :
Human, Mouse

Alternative names :
LRIG1 antibody; LIG-1 antibody; LIG1 antibody; leucine rich repeats and immunoglobulin like domains 1 antibody

Immunogen :

Isotype :
Rabbit IgG

Preparation :
Antigen: Recombinant fusion protein containing a sequence corresponding to amino acids 35-220 of human LRIG1 (NP_056356.2).

Clonality :
Polyclonal

Formulation :
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Storage instructions :
Store at -20℃. Avoid freeze / thaw cycles.

Applications :
WB 1:1000 – 1:2000

Background :
Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.

References :

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Efavaleukin alfa Autophagy
Insulin Receptor Beta Rabbit mAb Purity & Documentation
Ku80 Antibody: Ku80 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 83 kDa, targeting to Ku80. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human.

Share this post on:

Author: Gardos- Channel